Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up

C van Herpen; V Vander Poorten; A Skalova; C Terhaard; R Maroldi; A van Engen; B Baujat; L D Locati; A D Jensen; L Smeele; J Hardillo; V Costes Martineau; A Trama; E Kinloch; C Even; J-P Machiels; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

doi:10.1016/j.esmoop.2022.100602

Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up

ESMO Open. 2022 Dec;7(6):100602. doi: 10.1016/j.esmoop.2022.100602. Epub 2022 Nov 2.

Authors

C van Herpen¹, V Vander Poorten², A Skalova³, C Terhaard⁴, R Maroldi⁵, A van Engen⁶, B Baujat⁷, L D Locati⁸, A D Jensen⁹, L Smeele¹⁰, J Hardillo¹¹, V Costes Martineau¹², A Trama¹³, E Kinloch¹⁴, C Even¹⁵, J-P Machiels¹⁶; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Affiliations

¹ Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; Multidisciplinary Salivary Gland Society, Geneva, Switzerland. Electronic address: https://twitter.com/myESMO.
² Multidisciplinary Salivary Gland Society, Geneva, Switzerland; Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
³ Multidisciplinary Salivary Gland Society, Geneva, Switzerland; Department of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.
⁴ Multidisciplinary Salivary Gland Society, Geneva, Switzerland; Department of Radiotherapy, University Medical Center, Utrecht, The Netherlands.
⁵ Department of Radiology, ASST Spedali Civili Brescia-University of Brescia, Brescia, Italy.
⁶ Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
⁷ Department of Otorhinolaryngology, Head and Neck Surgery, Sorbonne Université Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France.
⁸ Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
⁹ Faculty of Medicine, Philipps-University Marburg, Marburg; Department of Radiation Oncology, University Hospitals Gießen and Marburg (UKGM) Ltd, Gießen, Germany.
¹⁰ Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek Ziekenhuis & Amsterdam UMC, Amsterdam.
¹¹ Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
¹² Department of Pathology, CHU Montpellier, Montpellier, France.
¹³ Evaluative Epidemiology, Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁴ Salivary Gland Cancer UK, London, UK.
¹⁵ Head and Neck Department, Gustave Roussy, Paris; French Network for Rare Head and Neck Cancers, Paris, France.
¹⁶ Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels; Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Abstract

•
This ESMO–EURACAN Clinical Practice Guideline provides key recommendations for managing salivary gland cancer.
•
The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up.
•
Treatment algorithms for parotid, submandibular, sublingual and minor salivary gland cancer are provided.
•
The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe.
•
Recommendations are based on available scientific data and the authors’ collective expert opinion.

Keywords: ESMO–EURACAN Clinical Practice Guideline; diagnosis; follow-up; salivary gland cancer; treatment.

Publication types

Practice Guideline

MeSH terms

Adult
Europe
Follow-Up Studies
Humans
Medical Oncology
Salivary Gland Neoplasms* / diagnosis
Salivary Gland Neoplasms* / therapy